Introduction
The amino acid ],-glutamate is the principal excitatory neurotransmitter in the central nervous system. Through its interaction with a broad variety of receptors present at the surface of responding cells, 1.-glutamate has been proposed to be involved in learning activity and memory acquisition, but also in neurotoxicity and diverse neurological disorders. Distinct families of glutamate receptors have been identified and these are either directly coupled to changes in cation conductance (ionotropic receptors) or to GTP-binding proteins (metabotropic receptors) (reviewed in [ 11) . Ionotropic glutamate receptors (iGlu receptors) are involved in triggering the immediate actions of released glutamate at the postsynaptic neuron. Metabotropic glutamate (mGlu) receptors are involved in the control of glutamatergic neurotransmission through the modulation of glutamate release at a presynaptic level and its actions at a postsynaptic level, and therefore have been proposed to have important regulatory roles in synaptic plasticity and neuronal excitability [l]. In the central nervous system, the nature of glutamate transmission is dependent on the combinations of these different subtypes of receptors at the synapse [2] . Although the physiological activities of mGlu receptors seem to be restricted to the central nervous system, a substantial proportion of the information currently accruing on mGlu receptor function is derived from experiments performed in heterologous expression systems, which often utilize non-neuronal mammalian cell models. This review provides an overview of the informa- tion derived from the use of such systems in the characterization of the properties of mGlu receptors, but we also assess critically the limitations and the possible risks of extrapolating data derived from studies in model cells to neuronal systems.
The structure of mGlu receptors
Molecular cloning studies have revealed the existence of a large family of mGlu receptors containing at least eight different subtypes, with most of these displaying alternative splicing at their C-terminus (reviewed in [3] ). Although all these receptors possess the seven-transmembrane (7-TM) domain structure common to G-protein-coupled receptors, they are clearly distinguished from the vast majority of the other members of this receptor superfamily by their particularly long extracellular N-terminus and by their relatively short intracellular and extracellular connecting loops. This structure is shared by some other recently cloned G-proteincoupled receptors, including the type B y-aminobutyric acid receptors [4] , the Ca2+-sensing receptor [S] and a subset of the pheromone receptor family [6] . These receptors do not present any significant sequence similarity to other G-protein-coupled receptors even within the 7-TM domains. Together, they constitute a subfamily of G-protein-coupled receptors in which the long extracellular N-terminus is proposed both to bind the agonist and then, after a conformational change, to act as an activator of the receptor [7, 8] . T h e principal structural and biochemical characteristics of the mGlu receptors are summarized in Table 1 .
On the basis of their amino acid sequence homologies, mGlu receptors can be subdivided into three groups [3] . Group I contains mGlul and mGlu5 receptors, group I1 contains mGluz and mGlu3 receptors, and group 111 contains mGlu4 and mGlu0.8 receptors. Structual homologies within each group coincide with common intracellular signalling pathways, indicative of the nature of the subsets of G-proteins activated. Group I mGlu receptors preferentially couple to the activation of phosphoinositide-specific Volume 
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phospholipase C through coupling to GqlIl, although the mGlu,, receptor splice variant has also been reported to activate adenylate cyclase and to mediate the release of arachidonic acid (presumably via the activation of a phospholipase A2 activity). Groups I1 and I11 mGlu receptors are coupled to the inhibition of adenylate cyclase through pertussis toxin-sensitive G (GIio)-proteins [3, 9] . A particular feature of the mGlu receptors seems to be the importance of the second intracellular (i2) loop in determining functional coupling to G-proteins [ 10,111. Also interesting is the evidence suggesting, at least for the mGlul receptor splice variants, a role for the intracellular C-terminus of the receptor in determining the potency of agonist [ 121. Therefore not only the expression of a particular mGlu receptor subtype but also the extent to which different alternatively spliced receptor variants are expressed might have a profound effect on 'shaping' a response of a neuron to glutamate. This might be a widespread phenomenon, given the existence of C-terminal alternative splicing of many of the mGlu receptor subtypes [3] .
Pharmacology of mGlu receptors
T h e pharmacological distinction between iGlu receptors and mGlu receptors was originally based on the specific recognition of the latter by the agonists 1-aminocyclopentane-1,3-dicarboxylic acid (groups I and 11) and I,-2-amino-4-phosphonobutyrate (L-AP~) (group 111). The classification of mGlu receptors into three groups is also supported by pharmacological studies, as their distinction is facilitated by the use of a large number of agonists and antagonists. Provided that iGlu receptor interactions are excluded, 1,-quisqualate, (S,2'R,3'R)-2-(2',3'-dicarboxycyclopropy1)glycine and r,-AP4 are specific agonists of group I, I1 and I11 mGlu receptors respectively, whereas 7-(hydroxyimino) cyclopropan [b] chromen-la-carboxylic acid ethyl ester, (2S,3S,4S)-2-methyl-2-(carboxycyclopropy1)glycine and (R,S)-a-methylserine-0-phosphate are relatively specific antagonists of groups I, I1 and I11 mGlu receptors respectively [9,13-1.51. In contrast with the increasing range of agonists and antagonists that can distinguish between mGlu receptor groups 1-111, there is only a small number of highly specific agonists or antagonists that exhibit pharmacological discrimination within mGlu receptor subgroups (e.g. between mGlul and mGlu5 receptors). T h e classification of the mGlu receptors, the transduction pathways that they activate and their respective pharmacologies are presented in Table 2 .
Heterologous expression of mGlu receptors
The use of brain tissue preparations, or neurons in primary culture, for the study of the pharmacological and biochemical properties of Table 2 Biochemical and pharmacological classification of the mGlu receptors Transiently transfected human embryonic kidney (HEK) cells and pig kidney epithelial (LLC-PK1) cells expressing different mGlu receptors have been widely used as models for the study of these receptors [18] [19] [20] [21] . However, quantitative measures of the receptor expression levels in such transfected cell models have proved problematic because of the lack of specific radioligands for each subtype. As a consequence, receptor density is usually assessed in immunoblotting experiments with receptor subtypespecific antisera. Less frequently, stable expression of mGlu receptor in HEK, Chinese hamster ovary (CHO), baby hamster kidney (BHK) and adenovirus-transformed Syrian hamster AV12 cells has also been reported [22- 261. However, it seems that an additional problem observed with these transfected cells is the difficulty of obtaining and maintaining the stable expression of functional mClu receptors at a constant level.
Although these transfected cell lines constitute convenient models for the study of mGlu receptor properties, an analysis of the recent literature reveals important discrepancies between studies performed with different cell lines transfected with identical cDNA sequences. Significant variation in the efficacies and/or potencies of different mGlu receptor agonists has been reported [27, 28] . Such variation is not restricted to agonist pharmacology: an interesting example of conflicting data on antagonists arises from studies reporting the activity of cc-methyl-4-carboxyphenylglycine (MCPG) at the recombinant mGluS receptor. Thus MCPG has been reported to antagonize both 1,-quisqualateand i>-glutamate-stimulated responses in transfected L(tk-) mouse fibroblast cells [28] . However, Brabet et al. [19] have reported that antagonist activity is dependent on the nature of the agonist causing mGlu receptor activation, as only the response to 1,-quisqualate was inhibited by the antagonist, whereas that stimulated by i>-glutamate was unaffected by MCPG [19] . In addition to such pharmacological discrepancies being reported, major discordances concerning differences in the biochemical coupling of mGlu receptors with intracellular transduction pathways are also commonplace. One explanation that can account for some, but not all, of these discrepancies between studies performed in heterologous expression models could be based on the variations in receptor densities between model systems. As already mentioned, the question of receptor expression level is particularly difficult to assess for mGlu receptors because of the absence of satisfactory high-affinity, high-specific-activity radioligands. Differences in the density of functional (cell-surface) receptors can result in differences in the 'receptor reserve', which will affect the potency and efficacy of both positive and inverse agonists [35] . Although the coupling of some mGlu receptors is rather complex, possibly involving efficient coupling to multiple G-proteins [9] , it has also been proposed that increasing the expression of G-protein-coupled receptors can lead to increasingly promiscuous coupling to multiple G-protein species [ 361. Similarly, the constitutive activity of G-proteincoupled receptors might also depend on the density of receptors [37, 38] . This has been shown for the mGlulz receptor, in which constitutive activity has been shown to increase proportionately with receptor expression [20] . In addition, the nature of the cell type chosen for heterologous expression studies might also govern the properties of the expressed receptor. For example, the molecular processing of newly synthesized receptors might be different from one cell to another. This possibility has been highlighted by immunocytochemistry studies that have shown a widespread distribution of the mGlulz receptor in transfected BHK cells [33] , whereas the same receptor was found to be targeted principally to the plasma membrane in transfected HEK cells [12] . In the same way, differences in the nature of the functional coupling of the receptors might also reflect the nature of the endogenously expressed G-protein complement of a given cell.
Glutamate-induced regulation of mGlu receptors
In addition to these possible pitfalls of using transfected cells for the study of G-proteincoupled receptors, a further problem observed when studying glutamate receptors in cell culture is the presence of 1.-glutamate in the cell culture medium. Even when care is taken to avoid the addition of any exogenous 1,-glutamate, cultured cells can release this amino acid into the incubation medium. This has been observed for BHK cells 
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Inducible expression of mGlu receptors
During the past few years, different systems of controlled heterologous expression have been developed by using inducible or repressible transcription promoters. The use of such systems allows cell lines to be established in which the expression of any cloned gene can be maintained 'silent' and can be rapidly induced by the addition of a chemical inducer to the culture medium. Controlled expression of adrenoceptors has previously been achieved in transfected DDTl MF-2 cells by using an isopropylp-r,-thiogalactoside (1PTG)-inducible system [46] . More recently, dexamethasone-controlled expression of the human mGlul,{ and mGluSa receptors has been reported in CHO cells [28] . By using the IPTG-inducible system, we have developed stably transfected CHO [31] and HEK cells (E. Hermans, S. R. Nahorski and R. A. J.
Challis, unpublished work) expressing 'silently' the human mGlulz receptor. The maintenance of receptor expression at very low levels during the initial transfection and clonal selection, and during the normal passaging of cells, prevents any possibility of prolonged activation of the 
Conclusion
The results summarized here highlight the contributions made to our understanding of the properties of single mGlu receptor subtypes by using heterologous expression systems. However, as discussed above, this approach is not without its own set of problems and limitations. Regarding the potential difficulties posed in determining the density of mGlu receptors in these model systems (but see [48, 49] ), as well as the possible receptor adaptations caused by glutamate in the incubation medium of cultured cells, the use of inducible mammalian cell models might prove to be extremely useful. In addition, heterologous expression systems provide a critical research tool for the discovery of new specific agonists and antagonists for each of the mGlu receptor subtypes, as they can provide sufficient cells 'in bulk' to allow high-throughput screening to be applied. Furthermore, inducible expression systems allow the 'titration' of physiologically relevant densities of mGlu receptors to be expressed at the cell surface ( [31] , and E. Hermans, R. A. J. Challiss and S. R. Nahorski, unpublished work), providing an ideal system in which to assess the efficacy, as well as the potency, of novel mGlu receptor agonists, and to establish the preferred downstream G-protein coupling partners of the different mGlu receptors [49] . Ultimately, however, heterologous expression in neuronal cell backgrounds [Sl] will be required to address more functional aspects of mGlu receptor modulation of synaptic activities in physiological and pathophysiological circumstances. Prog. Neurobiol. 54, Volume 27
